← All trials
NCT05914194
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Jan 15, 2025
- Completion date
- Feb 15, 2025
- First posted
- Jun 22, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NLS Pharma Inc.Lead sponsor
- NLS Pharma Inc.Study chair
- NLS Pharma Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.